Clinical Trials on Human Papilloma Virus Infection Type 11

Total 8077 results

Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Hepatitis C Infection With HIV Co-Infection

United Kingdom, Germany
Karolinska Institutet

Enrolling by invitation

Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection (NPA-DC)

RSV Infection | SARS CoV 2 Infection | Influenza B Virus Infection | Influenza A Infection

Sweden
ViiV Healthcare
GlaxoSmithKline

Completed

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Infection, Human Immunodeficiency Virus I
Vancouver Infectious Diseases Centre

Unknown

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Drug Use | Human Immunodeficiency Virus I Infection

Canada
Université Catholique de Louvain
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Optimization of Darunavir Therapy and Dosage Recommendations

Human Immunodeficiency Virus I Infection

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

Infection, Human Immunodeficiency Virus

Argentina
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Infection, Human Immunodeficiency Virus

United States, France, Germany, Canada, Spain, United Kingdom, Mexico, Italy, Argentina, Chile, South Africa, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

Fosamprenavir Versus Other Protease Inhibitors

Infection, Human Immunodeficiency Virus I

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Mills Clinical Research
ViiV Healthcare

Unknown

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC (STRUCTR)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Relative Bioavailability Study

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

No longer available

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Infection, Human Immunodeficiency Virus

Belgium, Russian Federation, Italy, South Africa, Argentina, Switzerland, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Infection, Human Immunodeficiency Virus

United States, France, Spain, Canada, Italy
ViiV Healthcare
GlaxoSmithKline

Withdrawn

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

Infection, Human Immunodeficiency Virus I

United States
ViiV Healthcare

Completed

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Withdrawn

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Completed

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Infection, Human Immunodeficiency Virus

United States, Spain, France, United Kingdom, Chile, Brazil, Italy, Portugal
Nova Southeastern University
National Institute of Mental Health (NIMH)

Completed

An Automated, Tailored Information Application for Medication Health Literacy

Human Immunodeficiency Virus I Infection

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Protease Inhibitors

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Hospices Civils de Lyon

Terminated

Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses (FXR#2)

Human Immunodeficiency Virus I Infection

France
Fred Hutchinson Cancer Center
University of Washington

Completed

MMF for HIV Reservoir Reduction

Human Immunodeficiency Virus I Infection

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study of Combined Oral Contraceptive Effects in Female Subjects

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Infection, Human Immunodeficiency Virus
ViiV Healthcare

Completed

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

GSK706769/KALETRA Drug-drug Interaction Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Single and Repeated Dose Escalation Study of GSK2838232

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States

Clinical Trials on Human Papilloma Virus Infection Type 11

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations